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506Clopidogrel efﬁcacy in high-risk
coronary artery disease (CAD)
has been demonstrated in major
trials and recognized by regulatory
agencies and in treatment guide-
lines (1). However, recent analyses
of major trials demonstrated a
substantial cardiovascular event
reduction with clopidogrel therapy
in smokers but not in nonsmok-
ers, a phenomenon termed the
“smokers’ paradox” (2). It has been
reported that smoking status
inﬂuences clopidogrel pharmaco-
dynamics (PD) in healthy volun-
teers, patients with acute coronary
syndromes, and patients treated
with percutaneous coronary inter-
vention (PCI) (3–5). An explana-
tion for the smokers’ paradox is
cytochrome P450 (CYP) 1A2 and
CYP2B6 induction by cigarette
smoking, resulting in greater clo-
pidogrel active metabolite (AM)
generation (6). To the best of
our knowledge, there have been
no prospective studies evaluating
the effect of smoking status on
both clopidogrel and prasugrel
pharmacokinetics (PK) and PD.See page 513
Drug–drug interactions and carriage of (CYP) 2C19 loss-
of-function alleles have been implicated in clopidogrel
response variability, high on-treatment platelet reactivity
(HPR), and adverse clinical outcomes. CYP1A2 is also
involved in clopidogrel biotransformation but has received
less attention (7).
The goal of the current study was to assess the effect of
smoking status on the PK and PD of clopidogrel andry Channel, and Pri-Med; holds stock or
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2012; revised manuscript received February 21,prasugrel therapy in aspirin-treated patients with stable
CAD. We hypothesized that smoking status inﬂuences
clopidogrel but not prasugrel AM concentrations and anti-
platelet effects, and that prasugrel antiplatelet effects are
greater than clopidogrel regardless of smoking status.
Methods
PARADOX was a prospective, randomized, double-blind,
double-dummy, placebo-controlled, crossover investigation
conducted at 6 centers in the United States between
November 18, 2010, and September 21, 2011. The
respective investigational review boards approved the study,
and patients provided written informed consent.
Study design. Patients (18 to 75 years of age) with docu-
mented stable CAD receiving 81 to 325 mg of aspirin therapy
daily were enrolled. Exclusion criteria were: weight <60 kg,
bare-metal or drug-eluting stenting within 12 months, history
of bleeding diathesis, transient ischemic attack, stroke, hepatic
disease orHIV,pregnancy, antithrombotic treatment other than
aspirin, use of proton pump inhibitors or drugs or dietary
products that strongly inhibit or induce CYP within 10 days,
nonsteroidal anti-inﬂammatory drug use >3 doses per week,
platelets <100,000/mm3 or >500,000/mm3, hemoglobin
<10 g/dl, and indication for thienopyridine therapy.
Patients were stratiﬁed according to smoking status before
randomization (1:1) to receive 10 days of clopidogrel (75 mg
daily) or prasugrel (10 mg daily) followed by a 14-day washout
and crossover period (Fig. 1). Randomization occurred by an
interactive voice response system/Web response system.
Compliance was conﬁrmed by a dosing diary and assessment of
tablet counts.
Smoking status. Urine cotinine concentrations were deter-
mined at screening by using Accutest NicAlert (Jant Pharmacal
Corporation, Encino, California). Patients who reported
smoking0.5 pack of cigarettes per day with aNicAlert level of
6 were enrolled in the smoking group and those who reported
being nonsmokers with a NicAlert level of 0, 1, or 2 were
enrolled in the nonsmoking group.
Blood sampling. Blood for PD and genotyping was
collected as previously described (5,8,9). PD measurements
were performed at baseline (visits 2 and 4) and at the end of
active treatment (visits 3 and 5) just before the 10th (last)
maintenance dose. PK samples were collected at 0.5, 1, 2, 4,
and 6 hours after the 10th maintenance dose.
Platelet function. The VerifyNow P2Y12 and vasodilator-
stimulated phosphoprotein phosphorylation (VASP-P) (Bio-
cytex, Inc., Marseille, France) assays, which are methods of
quantifying P2Y12 receptor reactivity, were performed as
previously described (5,9).
Pharmacokinetics. Prasugrel and clopidogrel metabolite
concentrations were determined in stabilized plasma samples
by using high-performance liquid chromatography with
mass spectrometric detection as previously described (10,11).
CYP1A2 activity. CYP1A2 activity was determined by the
ratio of paraxanthine/caffeine 6 hours after oral administration
Screening
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Figure 1 Study Design
Subjects were stratiﬁed according to smoking status in a 1:1 ratio and randomly assigned to 1 of 2 double-blind treatment sequences. CYP1A2 ¼ cytochrome P450 1A2;
PFT ¼ platelet function testing; PK ¼ pharmacokinetics. All patients received the same aspirin dose from randomization throughout the study.
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507of 100 mg of caffeine (JET-ALERT, Bell Pharmaceuticals,
Minneapolis, Minnesota) (12). Caffeine was administered
with the 10th maintenance dose of study medication, and all
caffeine intake was prohibited 24 hours before administra-
tion of caffeine. Plasma concentrations of paraxanthine and
caffeine were determined by using a high-performance liquid
chromatography with mass spectrometric method.
CYP2C19 genotyping. Common loss-of-function variants
of CYP2C19 (*2,*3) and the common gain-of-function
variant (*17) were identiﬁed by using a TaqMan assay, and
CYP2C19 metabolizer status was categorized as either
extensive metabolizers (EMs) (*1/*1, *1/*17, *17/*17) or
reduced metabolizers (RMs) (*2/*2, *1/*2) (8).
Safety. An adverse event within 14 days after the last dose
was any untoward event. Treatment-emergent adverse
events were adverse events that started or worsened in
severity on or after the ﬁrst dose of study medication.
Statisticalmethods. PRIMARYANALYSIS. The ﬁrst co-primary
endpoint was device-reported inhibition of platelet aggre-
gation (DR-IPA) in smokers versusnonsmokers after 9 days
of clopidogrel therapy. The second co-primary endpoint
was DR-IPA in prasugrel-treated smokers versus
clopidogrel-treated smokers. A linear mixed-effects model
for the crossover design with ﬁxed effects of smoking
status, sequence, treatment, period, smoking status 
treatment, and a random effect of subject (smoking 
sequence) was used for comparisons between groups.
SECONDARY ANALYSES. The secondary analyses included: 1)
DR-IPA in prasugrel-treated smokers versus prasugrel-
treated nonsmokers, in prasugrel-treated nonsmokers versus
clopidogrel-treated nonsmokers, and in prasugrel-treated
nonsmokers versus clopidogrel-treated smokers; and 2) all of
these comparisons and the comparisons between clopidogrel-treated smokers and nonsmokers and between prasugrel-
treated smokers and clopidogrel-treated smokers. The
analyses included calculated inhibition of platelet aggregation
(C-IPA), P2Y12 reaction units (PRU), and platelet reactivity
index (PRI) after 9 days of therapy. A post hoc analysis was
conducted by using C-IPA to compare clopidogrel-treated
smokers and nonsmokers and prasugrel-treated smokers and
clopidogrel-treated smokers. For the secondary endpoints,
summary statistics and 95% conﬁdence intervals (CIs) were
used for between-group comparisons. A logistic regression
analysis of responder rate according to treatment and smoking
status was conducted by using a generalized mixed-effects
model for the crossover design, with ﬁxed effects of smoking
status, sequence, treatment, period, and smoking status 
treatment, and a random effect of subject (smoking status 
sequence). Signiﬁcance for statistical tests was evaluated at the
p ¼ 0.05 level. All analyses were conducted by using SAS
version 9.2 (SAS Institute, Inc., Cary, North Carolina).
Sample size. For the co-primary endpoints’ sample size
calculations, no type I error rate was adjusted, and both co-
primary endpoints were tested at the 0.05 level by using a
2-sample Student t test to demonstrate a signiﬁcant difference
between groups (clopidogrel-treated smokers vs. clopidogrel-
treated nonsmokers). We estimated a 15% difference in DR-
IPA between smokers and nonsmokers. A sample size of 108
patients (54 smokers and 54 nonsmokers) was required given
the assumption of an SD of 24%, power of 80%, dropout rate
of 25%, and equal stratiﬁcation between groups.
Results
Patients. Among 170 patients screened, 110 were
randomized; 97% completed treatment period 1, 88%
completed treatment period 2, and 88% completed both
Table 1
Patient Demographics, Medical History,
ConcomitantMedications, andBaseline Laboratory Data
Variable
Total Group
(n ¼ 110)
Smokers
(n ¼ 54)
Nonsmokers
(n ¼ 56)
Demographics
Age (yrs) 59.4  8 58  8 61  8
Male 79 (72) 37 (68) 42 (75)
BMI (kg/m2) 31  6 30  5 32  6
Ethnicity
White 85 (77) 41 (76) 44 (79)
African American 23 (21) 11 (20) 12 (21)
Other 2 (2) 2 (3.7) 0 (0)
Medical history
Smoking (current) 54 (49) 54 (100) 0 (0)
Cardiovascular history 105 (95) 53 (98) 52 (93)
Hypertension 76 (69) 40 (74) 36 (64)
Hyperlipidemia 103 (94) 52 (96) 51 (91)
Diabetes 31 (28) 13 (24) 18 (32)
Previous MI 50 (45) 30 (56) 20 (36)
Previous CABG 42 (38) 15 (28) 27 (48)
Previous PCI 93 (85) 49 (91) 44 (79)
Baseline medications
Statins 76 (69) 37 (68) 39 (70)
ACE inhibitors 40 (36) 19 (35) 21 (37)
Beta-blockers 65 (59) 29 (54) 36 (64)
Organic nitrates 10 (9) 4 (7) 6 (11)
PPI 11 (10) 5 (9) 6 (11)
Baseline laboratory data
WBC (1,000/mm3) 7.4  2.0 8.3  2.0 6.6  2.0
Platelets (1,000/mm3) 229  56 239  60 219  53
Hematocrit (%) 43  3 44  4 42  3
Creatinine (mmol/l) 94  23 91  23 96  23
Total cholesterol (mg/dl) 178  42 185  47 170  36
Uric acid (mg/dl) 6.2  1.5 6.0  1.2 6.6  1.7
Values are mean  SD or n (%).
ACE ¼ angiotensin-converting enzyme; BMI ¼ body mass index; CABG ¼ coronary artery bypass
graft; CAD ¼ coronary artery disease; Hb ¼ hemoglobin; MI ¼ myocardial infarction; PCI ¼
percutaneous coronary intervention; PPI ¼ proton pump inhibitor; WBC, white blood cells.
Figure 2
Inhibition of Platelet Aggregation by
Treatment and Smoking Status
(A) Device-reported inhibition of platelet aggregation (IPA) and (B) calculated IPA.
Data are presented as least squares (LS) mean  SE. Device reported-inhibition of
platelet aggregation (DR-IPA) is reported using post-dosing BASE (BASEt) and PRU
(PRUt): DR-IPA (%) ¼ 100  [(BASEt – PRUt)/BASEt]. Calculated inhibition of
platelet aggregation (C-IPA), using pre-dosing PRU (PRUb) and post-dosing PRU
(PRUt) was determined as follows: C-IPA (%) ¼ 100  [(PRUb – PRUt)/PRUb]. In the
VerifyNow assay, the second channel contains ﬁbrinogen-coated polystyrene
beads, 3.4 mM iso-thrombin receptor activating peptide [iso-TRAP: protease-acti-
vated receptor (PAR)-1 agonist] and PAR-4 activating peptide (PAR-4 AP); this
channel estimates maximal platelet function independent of P2Y12 receptor
blockade and is reported as “BASE”.
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508treatment periods. Eight patients discontinued due to
a protocol violation, 4 because of an adverse event, and
1 withdrew consent. Demographic characteristics and con-
comitant medications were similar between groups except
for a higher body mass index in the nonsmokers (p ¼ 0.035)
(Table 1). Aspirin doses were 81 mg daily (61%) and
325 mg daily (39%). Overall compliance was 99.8%.
Platelet function. In clopidogrel-treated patients, baseline
PRU was 298  56 and 314  45 in smokers and
nonsmokers, respectively. In prasugrel-treated patients,
baseline PRU was 310  50 and 309  48 in smokers and
nonsmokers.
After 9 days of clopidogrel therapy, DR-IPA trended to
be lower in nonsmokers than smokers (p ¼ 0.062). DR-IPA
was higher in prasugrel-treated smokers than in clopidogrel-
treated smokers (p < 0.0001) (Fig. 2A, Table 2).
There was a signiﬁcant increase in platelet inhibition
according to C-IPA in clopidogrel smokers compared with
clopidogrel-treated nonsmokers (p ¼ 0.043) as well as in
prasugrel-treated smokers compared with clopidogrel-treated smokers (p < 0.0001) (Fig. 2B, Table 2). PRU
and PRI were lower in clopidogrel-treated smokers than in
nonsmokers (p ¼ 0.0048 and p ¼ 0.042, respectively). PRU
and PRI were lower in prasugrel-treated smokers than in
clopidogrel-treated smokers (p < 0.0001 for both).
Prasugrel treatment was associated with a greater anti-
platelet response compared with clopidogrel as determined
Table 2 Mean Treatment Differences for DR-IPA, C-IPA, PRU, and VASP-PRI
Analysis/Treatment Comparison
DR-IPA (%) C-IPA (%) PRU VASP-PRI (%)
LS Mean
Treatment
Difference p Value
LS Mean
Treatment
Difference p Value
LS Mean
Treatment
Difference p Value
LS Mean
Treatment
Difference p Value
Co-primary endpoints
Clopidogrel-treated smokers versus clopidogrel-treated nonsmokers 7.7  4.1 0.062 9.1  4.4 0.043 36.2  12.7 0.0048 7.6  3.7 0.042
Prasugrel-treated smokers versus clopidogrel-treated smokers 31.8  3.4 <0.0001 32.7  4.0 <0.0001 93.8  11.5 <0.0001 22.7  3.2 <0.0001
Secondary endpoints
Prasugrel-treated smokers versus prasugrel-treated nonsmokers 4.8  4.1 0.244 6.9  4.4 0.120 21.2  12.5 0.0924 5.8  3.7 0.118
Prasugrel-treated nonsmokers versus clopidogrel-treated nonsmokers 34.7  3.2 <0.0001 34.9  3.8 <0.0001 108.8  10.9 <0.0001 24.5  3.0 <0.0001
Prasugrel-treated nonsmokers versus clopidogrel-treated smokers 27.0  4.1 <0.0001 25.8  4.5 <0.0001 72.6  12.7 <0.0001 16.9  3.8 <0.0001
Values are mean  SE.
C-IPA ¼ calculated inhibition of platelet aggregation; DR-IPA ¼ device-reported inhibition of platelet aggregation; LS ¼ least squares; PRU ¼ P2Y12 reaction units; VASP-PRI ¼ vasodilator-stimulated phosphoprotein phosphorylation-platelet reactivity index.
Table 3 Prevalence of Patients With High Platelet Reactivity According to Treatment and Smoking Status
Assay HPR Cutoff
Nonsmokers Smokers
Clopidogrel (%)
(n ¼ 54)
Prasugrel (%)
(n ¼ 52)
Odds Ratio
Estimate (95% CI) p Value
Clopidogrel (%)
(n ¼ 47)
Prasugrel (%)
(n ¼ 50)
Odds Ratio
Estimate (95% CI) p Value
PRU >235 38.9 3.8 17.11 (3.13–93.65) 0.001 23.4 2.0 16.54 (1.85–148.23) 0.013
>208 53.7 3.8 29.65 (5.72–153.76) <0.0001 38.3 4.0 15.32 (3.07–76.55) 0.001
PRI >50% 55.6 17.3 11.71 (2.95–46.52) 0.0006 48.9 4.0 58.64 (6.80–505.58) 0.0003
>60% 46.3 11.5 8.17 (2.41–27.67) 0.0009 31.9 2.0 29.19 (3.15–270.48) 0.003
CI ¼ conﬁdence interval; HPR ¼ high platelet reactivity; other abbreviations as in Table 2.
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510by DR-IPA, C-IPA, PRU, and PRI, regardless of smoking
status (p < 0.0001 for all comparisons) (Table 2). There
were no signiﬁcant differences in the antiplatelet response to
prasugrel associated with smoking according to DR-IPA,
C-IPA, PRU, and PRI (p > 0.05 for all). Although the
interaction between smoking status and treatment was not
signiﬁcant, the study was not powered to show a difference.
Sensitivity analyses. Results of the analyses of mean
DR-IPA, PRU, and VASP-PRI that adjusted for
differences in baseline characteristics by adding all
potential covariates to the mixed-effects model were
similar to those obtained for the full PD population (data
not shown).
High on-treatment platelet reactivity. Among clopidogrel-
treated patients, smoking was associated with a 2.06 (95%
CI: 0.80 to 5.32) and 1.86 (95% CI: 0.81 to 4.29) times
lower odds ratio estimate (ORE) for HPR as determined by
>235 PRU and >208 PRU cutoff values, respectively, and
1.34 (95% CI: 0.49 to 3.67) and 1.88 (95% CI: 0.74 to 4.75)
times lower ORE as determined by >50% PRI and >60%
PRI cutoff values, respectively (data not shown). Using all
4 deﬁnitions, the odds of occurrence of HPR were signiﬁ-
cantly lower for prasugrel-treated patients compared with
clopidogrel-treated patients regardless of smoking status
(p < 0.05 for all comparisons) (Table 3).
CYP1A2 activity. Overall, smokers had higher median
CYP1A2 activity than nonsmokers (2.2 vs. 1.1; p ¼ 0.01).
The median CYP1A2 activity was 2.1 and 2.3 for clopidogrel-
and prasugrel-treated smokers, respectively, and 1.1 and
1.0 for clopidogrel- and prasugrel-treated nonsmokers
(median difference 0.9 [p ¼ 0.0136 for clopidogrel treat-
ment] and 1.1 [p ¼ 0.0024 for prasugrel treatment]). No
difference in CYP1A2 activity was observed between
prasugrel-treated patients and clopidogrel-treated patients.
For a given therapy, there were no signiﬁcant differences in
least squares (LS) mean DR-IPA, PRU, or PRI betweenTable 4
Comparison of PK Parameters of the Act
Active and Inactive Metabolites of Clopi
Parameter
Smokers
Geometric
LS Means
Nons
Geo
LS M
Prasugrel active metabolite
Cmax (ng/ml) 42.6
AUC0–last (h $ ng/ml) 53.6
Clopidogrel active metabolite
Cmax (ng/ml) 13.5
AUC0–last (h $ ng/ml) 19.2
Clopidogrel inactive metabolite
Cmax (ng/ml) 2,080.9 2,3
AUC0–last (h $ ng/ml) 5,025.5 5,8
A mixed-effects model for the crossover design was performed on log-tran
effects for smoking status, treatment sequence, treatment, treatment perio
(smoking status  treatment sequence). Geometric LS means are the
back-transformation to the original scale. The 90% CIs are presented afte
clopidogrel Cmax and AUC0–last values had 90% CIs that fell outside of the 8
AUC0–last ¼ area under the curve up to the last sampling time; Cmax ¼ maxCYP1A2 activity categories (median or lower vs. higher than
the median, or between quartiles) (data not shown).
Pharmacokinetics. Geometric LS mean systemic exposure
(area under the curve [AUC]0–last) to AM was higher for
prasugrel compared with clopidogrel in both nonsmokers
(48.4 h $ ng/ml vs. 16.2 h $ ng/ml) and smokers (53.6 h $ ng/
ml vs. 19.2 h $ ng/ml). Smokers had 10.7% higher exposure
to the prasugrel AM and 18.4% higher exposure to the clo-
pidogrel AM (Table 4). Conversely, mean clopidogrel
inactive metabolite exposure was 13.6% lower in smokers.
The median time to maximum concentration of the prasugrel
AM was 0.5 hour in both smokers and nonsmokers, and for
clopidogrel AM, it was 0.8 hour for smokers and 1.0 hour
for nonsmokers.
After dose–weight adjustment, the AUC0–last geometric
LS mean ratios (90% CI) were: clopidogrel AM 111.4 (95.0
to 130.6); clopidogrel-inactive metabolite 80.3 (68.5 to
94.3); and prasugrel AM 102.7 (87.9 to 119.9). These data
indicate that the exposure to clopidogrel AM and the
inactive metabolite were not equivalent between smokers
and nonsmokers (the CIs for clopidogrel AM and the
inactive metabolite were outside the 0.80 to 1.25 interval
required for equivalence), whereas exposure to prasugrel AM
was equivalent in smokers and nonsmokers. The compari-
sons of the log-transformed PK parameters of the prasugrel
AM and the clopidogrel AM and inactive metabolite
between CYP1A2 categories (median or lower vs. higher
than the median or CYP1A2 quartiles) were not signiﬁcant
(data not shown).
CYP2C19 genotype. Eighty-six patients (80%) were EMs
(45 nonsmokers and 41 smokers) and 20 (19%) were RMs (10
nonsmokers and 10 smokers). Genotype information was
missing in 1 patient. There were no differences in genotype
distribution between treatment groups (data not shown).
CYP2C19 genotype did not inﬂuence exposure to the
AMs of either prasugrel or clopidogrel (EM/RM [95% CI]:ive Metabolite of Prasugrel and the
dogrel Between Smokers and Nonsmokers
mokers
metric
eans
Ratio of
Geometric
LS Means (%)
90% CI for
Ratio (%)
36.1 117.9 94.4–147.3
48.4 110.7 93.7–130.8
10.9 123.8 98.6–155.4
16.2 118.4 99.8–140.4
49.8 88.6 70.6–111.1
16.6 86.4 72.8–102.5
sformed pharmacokinetic (PK) parameters. The model included ﬁxed
d, and smoking status  treatment and a random effect for subject
LS means obtained from the mixed-effects model presented after
r back-transformation to the original scale. All mean prasugrel and
0% to 125% interval.
imum plasma concentration; other abbreviations as in Tables 2 and 3.
Table 5
DR-IPA by Treatment, Smoking, and CYP2C19 Genetically Determined
Metabolizer Status
n LS Mean (SE)
LS Mean  SE
Difference Between
Treatment p Value
Reduced metabolizers
Clopidogrel-treated smokers 10 20.2  5.79 9.1  8.40 0.285
Clopidogrel-treated nonsmokers 9 29.3  6.08
Prasugrel-treated smokers 10 68.1  5.79 47.9  6.38 <0.0001
Clopidogrel-treated smokers 10 20.2  5.79
Extensive metabolizers
Clopidogrel-treated smokers 36 44.0  3.39 12.8  4.54 0.006
Clopidogrel-treated nonsmokers 45 31.2  3.05
Prasugrel-treated smokers 39 70.8  3.26 26.8  3.71 <0.0001
Clopidogrel-treated smokers 36 44.0  3.39
CYP ¼ cytochrome P450; other abbreviations as in Table 2.
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511prasugrel 0.98 [0.79 to 1.23]; clopidogrel 1.17 [0.84 to
1.64]). LS mean DR-IPA was lower in clopidogrel-treated
nonsmokers compared with smokers with respect to EM
(p ¼ 0.0056) but did not differ in RMs (p ¼ 0.29) (Table 5).
The difference in LS mean DR-IPA between prasugrel-
treated smokers and clopidogrel-treated smokers was
signiﬁcant in both EMs (26.8%; p < 0.0001) and RMs
(47.9%; p < 0.0001).
Safety. Here were no serious bleeding events. Patients
treated with prasugrel had a greater occurrence of ecchy-
moses (2.8% vs. 0%).
Discussion
PARADOX is the ﬁrst prospective study to evaluate the
inﬂuence of smoking status on the PK and PD proﬁle of
clopidogrel and prasugrel. Nonsmokers had reduced
responsiveness to clopidogrel compared with smokers who
reported smoking 0.5 pack cigarettes per day and had a
NicAlert level of 6. Smoking was associated with approxi-
mately 2-fold decreased ORE for HPR during clopidogrel
therapy. However, smoking did not signiﬁcantly inﬂuence
the antiplatelet response to prasugrel, and a greater anti-
platelet effect and a markedly lower prevalence of HPR were
present after prasugrel treatment regardless of smoking
status. Smoking enhanced bioactivation of clopidogrel as
reﬂected by greater AM exposure after adjustment for
weight and lower inactive metabolite exposure.
In a post-hoc analysis, current smoking was associated
with lower platelet reactivity and greater clopidogrel-induced
inhibition that was dependent on the number of cigarettes
smoked per day (4). Subsequently, similar ﬁndings were
demonstrated in many, but not all, PD studies (3,13,14). A
nonsigniﬁcant decrease (p ¼ 0.062) in DR-IPA observed in
PARADOX may be related to use of the BASE value,
instead of a true pre-treatment PRU value for IPA deter-
mination. In addition, in the calculation of DR-IPA,
negative IPA is considered zero inhibition and may under-
estimate the degree of clopidogrel nonresponsiveness.Therefore, DR-IPA may not be an optimal surrogate for
IPA determined with a true baseline PRU measurement. In
line with our observations, the manufacturer of VerifyNow
has recently chosen to delete the DR-IPA and BASE
recordings from their device. Furthermore, C-IPA, deter-
mined with actual pre-treatment and post-treatment PRU
values, was signiﬁcantly greater and consistent with the
observations of signiﬁcantly lower PRU and VASP-PRI
values in clopidogrel-treated smokers.
The relation of platelet reactivity to ischemic event
occurrence may be sigmoidal, with the risk increasing greatly
above a certain threshold (7). The large body of translational
research data linking clopidogrel PD to clinical outcomes
has been based on PRU and PRI thresholds deﬁning HPR.
In PARADOX, a poorer antiplatelet response in non-
smokers during clopidogrel therapy was indicated by a
signiﬁcant difference of 36 PRUs (p ¼ 0.0048) and 7.6%
PRI (p ¼ 0.042) and an approximately 2-fold greater ORE
for HPR. A 4% increase in the primary ischemic endpoint
for every 10-unit increase in PRU (hazard ratio: 1.04 [95%
CI: 1.03 to 1.06]; p < 0.0001) has been reported (15).
In another study of clopidogrel-treated PCI patients, an
increase in 21 PRUs translated into a 1.6 times increase in
HPR prevalence and an increase in periprocedural myocar-
dial infarction (16). These results suggest that the modest
increase in platelet reactivity and HPR prevalence observed
in clopidogrel-treated nonsmokers in PARADOX may
inﬂuence clinical outcomes.
In PARADOX, the overall AM exposure (AUC0–last) was
numerically higher for prasugrel compared with clopidogrel
in both nonsmokers and smokers. A good correlation
between AM exposure and PD has been demonstrated for
both prasugrel and clopidogrel such that greater IPA during
therapy reﬂects increased AM generation (17). The mean
maximum concentration and mean AUC0–last of clopidogrel
inactive metabolite were greater in nonsmokers and are
consistent with other ﬁndings indicating less bioactivation in
nonsmokers (6). Importantly, after dose–weight normaliza-
tion, clopidogrel AM levels remained lower in nonsmokers.
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512The PK results of PARADOX support the hypothesis
that smoking enhances clopidogrel AM exposure and PD
response.
A sigmoidal maximum effect model to describe the
PK/PD relationship for prasugrel and clopidogrel has been
suggested (17). In PARADOX, an 18.4% increase in clo-
pidogrel AM exposure in smokers was associated with
signiﬁcantly lower PRU, PRI, and C-IPA values. Given that
exposure to clopidogrel AM resides on the steep portion of
the dose–response curve, relatively small changes in exposure
would be expected to result in more signiﬁcant changes in
PD. Given that prasugrel AM typically resides on the ﬂat
portion of the dose–response curve, consistent with the
sigmoidal maximum effect model, a 10.7% increase in
AUC0–last for prasugrel AM in smokers was associated with
a nonsigniﬁcant increase in antiplatelet effects.
Study limitations. PARADOX was powered at 80% to
detect a statistically signiﬁcant difference of 15% (assumed
SD of 24%) inDR-IPA between clopidogrel-treated smokers
and clopidogrel-treated nonsmokers. The actual effect size
(7.7  22% [approximate]) was smaller than predicted.
However, the signiﬁcantly higher PRUs and VASP-PRI, and
lower C-IPA and a higher prevalence ofHPR, in clopidogrel-
treated nonsmokers support our conclusions.
Greater CYP1A2 activity in smokers has been shown and is
consistent with our ﬁndings (41). The limited number of
patients (n¼ 45) with evaluable CYP1A2 data in PARADOX
may have precluded our ability to demonstrate a signiﬁcant
relation between CYP1A2 activity and PK. Cigarette
smoking may affect other factors involved in clopidogrel
metabolism that were not assessed in PARADOX. CYP2B6
is involved in both clopidogrel and prasugrel metabolism,
and a potential inﬂuence of smoking on CY2B6 should be
explored further (18). Finally, clopidogrel AM exposure was
not signiﬁcantly inﬂuenced by CYP2C19 genotype and may
be due to the small CYP2C19 RM sample size.
Conclusions
PARADOX is the ﬁrst prospective study to demonstrate
that clopidogrel-treated nonsmokers have an attenuated
PK and PD response compared with clopidogrel-treated
smokers and that prasugrel therapy is associated with
a greater antiplatelet effect compared with clopidogrel
therapy regardless of smoking status. The poorer antiplatelet
response in clopidogrel-treated nonsmokers may provide an
explanation for the reduced clinical beneﬁt of clopidogrel
treatment in nonsmokers observed in major randomized
trials and deserves further investigation.
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